Accumulating evidences have shown that selective antagonism of DUBs could be a promising treatment strategy for cancer therapy or resolving clinical chemoresistance problems, thus a number of DUB inhibitors are actually under preclinical studies and clinical trials [49, 50]. The gene discussed is ZUP1; the disease is cancer.